Scientific Publications Archive - Arvinas

Physicochemical Property Determinants of Oral Absorption for PROTAC® Protein Degraders

Protein Degradation Therapeutics: PROTAC® Drug Discovery at Arvinas

Small molecule PROTAC® hijacking and structural characterization of an E3 ligase, KLHDC2, for targeted protein degradation

Discovery & Optimization of PROTAC® Molecules That Selectively Reduce Mutant Huntingtin

Mechanisms of Acquired Resistance to ARV-471, a Novel PROTAC® Estrogen Receptor (ER) Degrader

Enhanced Efficacy of ARV-471, a Novel PROTAC® Estrogen Receptor Degrader, in Combination with Targeted Agents in ER+ Breast Cancer Models

Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer

Oral PROTAC® Degrader Molecules to Selectively Clear Proteins in Neurodegenerative Diseases

The Arvinas PROTAC® Discovery Engine: PROTAC Biophysical Characterization Fuels The Discovery Of Target And E3 Ligase Ligands For Optimized PROTAC Degrader Molecules

KRAS-Targeted PROTAC® Degraders are Broadly Efficacious Against KRAS Dependent Tumor Models